Chronic Obstructive Pulmonary Disease Clinical Trial
— REVASCOfficial title:
Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease
REVASC is a randomized, double-blind, placebo-controlled study which will involve 150
patients with chronic bronchitis and COPD diagnosed cardiovascular disease. The recruitment
period beginimg in the coming weeks, will last nine months. Patients included in the study
will receive treatment for three months with roflumilast 500 mg (75 patients) or placebo (75
patients) in a randomized manner. The CIBERES, as promoter of this study is expected to
release final results for the third quarter of 2013.
Eight centers in Madrid will be involved in this clinical trial: Fundación Jiménez Díaz,
Hospital La Princesa, Hospital Gregorio Maranon Hospital Clinico San Carlos, Hospital La
Paz, Hospital Ramón y Cajal Hospital Doce de Octubre and Hospital Puerta del Hierro.
Roflumilast is a potent phosphodiesterase-4 inhibitor (PDE4). Its clinical efficacy has been
studied in an extensive clinical program involving over 12,000 patients with COPD. In these
studies, roflumilast (in combination with long-acting bronchodilators) reduced the number of
exacerbations and improved lung function, especially in those patients with associated
chronic bronchitis.
Status | Not yet recruiting |
Enrollment | 150 |
Est. completion date | August 2012 |
Est. primary completion date | July 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 55 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Signed informed consent - 55-75 years of age - Current and former smokers >20 cigarettes pack-yr (if former smokers withdrawn >1 year) - Diagnosis COPD (GOLD criteria1 for more than a year before V0) - Presence of chronic bronchitis (cough and/or expectoration for more that 3 months/yr for more than 2 consecutive yrs. in the absence of other potential cause) - Post-bronchodilator FEV1<70% reference - Presence of established CVD, CVD equivalent or diabetes mellitus - Presence of chronic systemic inflammation, determined on: 1. Serum CRP = 2 and < 10 mg/l or 2. Serum fibrinogen > 518 mg/dl and Leucocytes > 8,6*106 /mm3 Exclusion Criteria: - Episode of COPD exacerbation and/or COPD treatment change during the last 2 months before V0 - History of asthma, significant residual lung lesions or bronchiectasis on chest x-ray - Apnea-hypopnea syndrome - Poorly controlled CVD risk factors (Table 2) and/or change in their treatment during the last 3 months before V0 - Clinically significant cardiac arrhythmias or valve disease - Severe concomitant immunological, inflammatory, infectious or neoplastic diseases - Moderate or severe hepatic insufficiency (B or C class, following Child-Pugh scale) - Severe neurologic and/or psychiatric disorder, including depression with suicidal ideas - Alcohol and/or drug abuse during the last 12 months before V0 - Hypersensitivity to roflumilast or to any of its excipients - Pregnancy or potential pregnancy - Participation in other clinical trial during the last 30 days before V0 - Language difficulties to follow the instructions of the study |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Spain | Spanish Research Center for Respiratory Diseases | Bunyola | Balearic Island |
Lead Sponsor | Collaborator |
---|---|
Spanish Research Center for Respiratory Diseases |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Endotelial function | 12 weeks | No | |
Secondary | Arterial siffness | 12 weeks | No | |
Secondary | Serum and plasma inflammation markers: (CRP, fibrinogen, leucocytes, interleukin (IL)-8, IL-6, IL-10, tumor necrosis factor alpha (TNFa), sICAM-1, MCP-1, PARC/CCL-18) | 12 weeks | No | |
Secondary | Serum oxidatrive stress markers: MPO, TRX | 12 weeks | No | |
Secondary | Serum endothelial dysfunction markers:TWEAKs, FasL, ADMA | 12 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|